Diet and weight: weekly semaglutide eased heart pressure in obesity and heart failure
☕ Includes a question for the family ↓
Diet and weightPart of a story we are following · 10 articles · See every update
If you think about diet and weight and what they mean for your heart, this trial brings good news. In a one-year trial of 81 adults with obesity and heart failure with preserved ejection fraction (HFpEF), people who took semaglutide (2.4 mg weekly) had pressure inside the heart during exercise that was 10.6 mmHg lower than people who took a placebo.
Even better, more than half of the people on semaglutide reached normal heart pressure, both at rest and during exercise. That is a real step toward a heart working under less strain.
How the study worked
Researchers randomly assigned 81 people (47 women) who had HFpEF and obesity to take either semaglutide or a placebo for 52 weeks. It was a double-blind trial, so neither the patients nor the researchers knew who got which. It was a small trial that lasted one year, and it measured pressure directly inside the heart. It was published on November 8, 2026 in Nature Medicine.
What they found
The main measure was wedge pressure, a direct reading of congestion in the heart. Lower is better. When the study began, wedge pressure during light exercise averaged 31.7 mmHg.
After 52 weeks, the semaglutide group’s exercise pressure had dropped by 9.8 mmHg. In the placebo group it had edged up by 0.9 mmHg. The gap between the two groups was 10.6 mmHg, or about 11 points.
The benefit showed up at rest too. Resting pressure was 7.1 mmHg lower with semaglutide than with placebo, about 7 points. At the start, resting pressure averaged 17.5 mmHg.
Then there is the headline number. In the semaglutide group, 53.7% of people reached what the researchers call hemodynamic remission. In the placebo group, 7.4% did. In plain words, more than half of the treated people saw their heart pressure return to normal.
What does remission mean here?
In this study, remission has a specific meaning. It means wedge pressure was normal both at rest and during exercise at the 52-week mark. It describes the pressure inside the heart, which the researchers measured directly.
The researchers say these results show semaglutide reduced pressure on the left side of the heart during exercise and at rest. That helps explain how the medicine can improve symptoms in people with HFpEF.
What you can do today
Take two minutes to write a short note on your phone. Put down your current weight, how you feel on stairs or a short walk, and one question: “Is semaglutide an option for me?” Bring the note to your next appointment. It gives you and your doctor a clear starting point.
Talk about it at home
Your heart works like a pump pushing water through a garden hose, and the fuller the hose gets, the harder the pump has to push. Scientists wanted to know whether the pressure inside the heart could ease, so they measured it directly, and they compared a group who got the real treatment with a group who got a look-alike with nothing in it. The groups were picked by chance, so the comparison would be fair, and the pressure eased in the treated group.
Try it at home
Ask a grandparent or another older person what games they played outside when they were young, the kind that made them breathe hard and laugh, and which one was their favorite.
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. Diet and weight: weekly semaglutide eased heart pressure in obesity and heart failure. Mongevity. Published November 10, 2026. Accessed November 22, 2026. https://mongevity.science/lifestyle/2026/11/semaglutide-heart-pressure-obesity-heart-failure/Mongevity Desk. Diet and weight: weekly semaglutide eased heart pressure in obesity and heart failure [Internet]. Mongevity; 2026 Nov 10 cited 2026 Nov 22]. Available from: https://mongevity.science/lifestyle/2026/11/semaglutide-heart-pressure-obesity-heart-failure/Mongevity Desk. (2026, November 10). Diet and weight: weekly semaglutide eased heart pressure in obesity and heart failure. Mongevity. https://mongevity.science/lifestyle/2026/11/semaglutide-heart-pressure-obesity-heart-failure/
<a href="https://mongevity.science/lifestyle/2026/11/semaglutide-heart-pressure-obesity-heart-failure/">Diet and weight: weekly semaglutide eased heart pressure in obesity and heart failure</a>
Free to share or quote with credit and a link.
Questions and answers
- What did the semaglutide trial find in people with obesity and HFpEF?
- Semaglutide lowered pressure inside the heart during exercise by 10.6 mmHg more than placebo after 52 weeks. It also lowered resting pressure.
- What is HFpEF?
- HFpEF stands for heart failure with preserved ejection fraction. It is a form of heart failure that the people in this trial had, along with obesity.
- How many people reached normal heart pressure?
- In the semaglutide group, 53.7% reached normal pressure at rest and during exercise. In the placebo group, 7.4% did.
- How big and how long was the trial?
- It included 81 people, 47 of them women, and lasted 52 weeks. It was a randomized, double-blind, placebo-controlled trial.





